Mannitol dry powder for inhalation: In patients with cystic fibrosis

Drugs

Volumn 72, Issue 10, 2012, Pages 1411-1421

  Burness, Celeste B ^a   Keating, Gillian M ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Adis Drug Profiles; Cystic fibrosis; Mannitol

Indexed keywords

ANTIBIOTIC AGENT; DORNASE ALFA; FLUCLOXACILLIN; MANNITOL; PLACEBO; SALBUTAMOL;

ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; ARTICLE; ASTHMA; BRONCHOSPASM; BRONCHUS MUCUS; CYSTIC FIBROSIS; DISEASE SEVERITY; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DYSPNEA; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HEMOPTYSIS; HUMAN; INHALATION; LOWER RESPIRATORY TRACT INFECTION; MAXIMUM PLASMA CONCENTRATION; PATIENT COMPLIANCE; THORAX PAIN; WHEEZING;

ADMINISTRATION, INHALATION; CYSTIC FIBROSIS; DRY POWDER INHALERS; FORCED EXPIRATORY VOLUME; HUMANS; MANNITOL; MOLECULAR STRUCTURE; MUCOCILIARY CLEARANCE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84863186511     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11208950-000000000-00000     Document Type: Article

References (24)

1. O'Sullivan BP, Freedman SD. Cystic fibrosis. Lancet 2009 May 30; 373: 1891-904
2. Cystic Fibrosis Foundation. Patient registry: annual data report 2009 [online]. Available from URL: http://www. cff.org/UploadedFiles/research/ ClinicalResearch/Patient-Registry-Report-2009.pdf [Accessed 2011 Nov 17]
3. Cystic Fibrosis Worldwide. What is cystic fibrosis? [online]. Available from URL: http://www.cfww.org/about/article/400/What-is-Cystic-Fibrosis [Accessed 2011 Nov 16]
4. UK CF Registry. Annual data report 2010 [online]. Available from URL: http://www.cftrust.org.uk/aboutcf/pub lications/cfregistryreports/UK-CF- Registry-Annual-Data-Report-2010.pdf [Accessed 2012 May 17]
5. Regnis JA, Robinson M, Bailey DL, et al. Mucociliary clearance in patients with cystic fibrosis and in normal subjects. Am J Respir Crit Care Med 1994 Jul; 150 (1): 66-71 (Pubitemid 24209938)
6. Bilton D, Robinson P, Cooper P, et al. Inhaled dry powder mannitol in cystic fibrosis: an efficacy and safety study. Eur Respir J 2011 Nov; 38 (5): 1071-80
7. Jones AM, Helm JM. Emerging treatments in cystic fibrosis. Drugs 2009; 69 (14): 1903-10
8. Wills PJ. Inhaled mannitol in cystic fibrosis. Expert Opin Invest Drugs 2007; 16 (7): 1121-6 (Pubitemid 47074166)
9. Aitken ML, Bellon G, De Boeck K, et al. Long-term inhaled dry powder mannitol in cystic fibrosis: an international randomized study. Am J Respir Crit CareMed 2012Mar 15; 185 (6): 645-52
10. Australian Government Department of Health and Ageing Therapeutic Goods Administration. Australian public assessment report for mannitol [online]. Available from URL: http://www.tga.gov.au/pdf/auspar/auspar-bronchitol. pdf [Accessed 2011 Nov 17]
11. Spector S. Use of mannitol inhalation challenge in assessment of cough. Lung 2010 Jan; 188 Suppl. 1: S99-103
12. Pharmaxis Pharmaceuticals Ltd. Bronchitol (mannitol) 40 mg inhalation powder, hard capsules: UK summary of product characteristics [online]. Available from URL: http://www.medicines.org.uk/EMC/medicine/26446/SPC/ Bronchitol+40+mg+inhalation+powder%2c+hard+capsules/[Accessed 2012May 8]
13. Teper A, Jaques A, Charlton B. Inhaled mannitol in patients with cystic fibrosis: a randomised open-label dose response trial. J Cyst Fibrosis 2011; 10 (1): 1-8
14. Daviskas E, Anderson SD, Jaques A, et al. Inhaled mannitol improves the hydration and surface properties of sputum in patients with cystic fibrosis. Chest 2010 Apr; 137 (4): 861-8
15. Jaques A, Daviskas E, Turton JA, et al. Inhaled mannitol improves lung function in cystic fibrosis. Chest 2008 Jun; 133 (6): 1388-96 (Pubitemid 351892995)
16. Robinson M, Daviskas E, Eberl S, et al. The effect of inhaled mannitol on bronchial mucus clearance in cystic fibrosis patients: a pilot study. Eur Respir J 1999 Sep; 14 (3): 678-85 (Pubitemid 29479736)
17. Bilton D, Aitken M, Fox H, et al. Inhaled dry powder mannitol in cystic fibrosis (CF): the microbiology demographics and results from the phase III studies (CF301 and CF302) [poster]. 34th European Cystic Fibrosis Conference; 2011 Jun 8-11; Hamburg
18. Yaghi A, Zaman A, Dolovich MB. The direct effect of hyperosmolar agents on ciliary beating of human bronchial epithelial cells. J Aerosol Med Pulm Drug Deliv 2012 Apr; 25 (2): 88-95
19. Daviskas E, Anderson SD, Brannan JD, et al. Inhalation of dry powder mannitol increases mucociliary clearance. Eur Resp J 1997 Nov; 10 (11): 2449-54 (Pubitemid 28048614)
20. Daviskas E, Anderson SD, Young IH, et al. Inhaled mannitol changes the sputum properties in asthmatics withmucus hypersecretion. Respirology 2007 Sep; 12 (5): 683-91 (Pubitemid 47414869)
21. Daviskas E, Anderson SD, Eberl S, et al. Inhalation of dry powder mannitol improves mucociliary clearance in patients with bronchiectasis. Amer J Respir Crit Care Med 1999 Jun; 159 (6): 1843-9
22. Aitken ML, Flume PA, Geller DE, et al. Efficacy and safety by age group from the phase III studies of Bronchitol (inhaled mannitol) in patients with CF [poster]. 25th Annual North American Cystic Fibrosis Conference; 2011 Nov 3-5; Anaheim (CA)
23. Bilton D, Robinson P, Cooper P, et al. Combined data from two phase III studies of Bronchitol (inhaled dry powder mannitol) in adult cystic fibrosis (CF) patients [poster]. 34th European Cystic Fibrosis Conference; 2011 Jun 8-11; Hamburg
24. Bilton D, Aitken M, de Boeck K, et al. Inhaled dry powder mannitol in cystic fibrosis (CF): impact on pulmonary exacerbations (PEs) in the phase III studies (CF-301 and CF-302) [abstract no. A-469-0005-00546 plus poster]. 35th European Cystic Fibrosis Society conference; 2012 Jun 6-9; Dublin